CA2564742C - Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists - Google Patents

Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists Download PDF

Info

Publication number
CA2564742C
CA2564742C CA2564742A CA2564742A CA2564742C CA 2564742 C CA2564742 C CA 2564742C CA 2564742 A CA2564742 A CA 2564742A CA 2564742 A CA2564742 A CA 2564742A CA 2564742 C CA2564742 C CA 2564742C
Authority
CA
Canada
Prior art keywords
methyl
azoniabicyclo
hydroxy
diphenyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2564742A
Other languages
English (en)
French (fr)
Other versions
CA2564742A1 (en
Inventor
Dramane I. Laine
Michael R. Palovich
Brent W. Mccleland
Christopher E. Neipp
Sonia M. Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2564742(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to CA2755954A priority Critical patent/CA2755954C/en
Publication of CA2564742A1 publication Critical patent/CA2564742A1/en
Application granted granted Critical
Publication of CA2564742C publication Critical patent/CA2564742C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
CA2564742A 2004-04-27 2005-04-27 Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists Expired - Lifetime CA2564742C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2755954A CA2755954C (en) 2004-04-27 2005-04-27 Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56562304P 2004-04-27 2004-04-27
US60/565,623 2004-04-27
PCT/US2005/014386 WO2005104745A2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2755954A Division CA2755954C (en) 2004-04-27 2005-04-27 Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists

Publications (2)

Publication Number Publication Date
CA2564742A1 CA2564742A1 (en) 2005-11-10
CA2564742C true CA2564742C (en) 2012-01-10

Family

ID=35242158

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2564742A Expired - Lifetime CA2564742C (en) 2004-04-27 2005-04-27 Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists
CA2755954A Expired - Lifetime CA2755954C (en) 2004-04-27 2005-04-27 Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2755954A Expired - Lifetime CA2755954C (en) 2004-04-27 2005-04-27 Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists

Country Status (38)

Country Link
US (9) US7498440B2 (cg-RX-API-DMAC7.html)
EP (3) EP1740177B1 (cg-RX-API-DMAC7.html)
JP (2) JP5014121B2 (cg-RX-API-DMAC7.html)
KR (2) KR101152032B1 (cg-RX-API-DMAC7.html)
CN (2) CN102040602A (cg-RX-API-DMAC7.html)
AP (1) AP2213A (cg-RX-API-DMAC7.html)
AR (1) AR050902A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005237576B2 (cg-RX-API-DMAC7.html)
BE (1) BE2014C063I2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0510170B8 (cg-RX-API-DMAC7.html)
CA (2) CA2564742C (cg-RX-API-DMAC7.html)
CY (3) CY1113196T1 (cg-RX-API-DMAC7.html)
DK (2) DK1740177T3 (cg-RX-API-DMAC7.html)
EA (2) EA015033B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066940A (cg-RX-API-DMAC7.html)
ES (2) ES2600405T3 (cg-RX-API-DMAC7.html)
FR (1) FR14C0075I2 (cg-RX-API-DMAC7.html)
HR (2) HRP20120832T1 (cg-RX-API-DMAC7.html)
HU (2) HUE031304T2 (cg-RX-API-DMAC7.html)
IL (1) IL178152A (cg-RX-API-DMAC7.html)
LT (1) LT2570128T (cg-RX-API-DMAC7.html)
LU (1) LU92565I2 (cg-RX-API-DMAC7.html)
MA (1) MA28631B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06012405A (cg-RX-API-DMAC7.html)
MY (1) MY144753A (cg-RX-API-DMAC7.html)
NL (1) NL300694I2 (cg-RX-API-DMAC7.html)
NO (3) NO338959B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ549997A (cg-RX-API-DMAC7.html)
PE (1) PE20060259A1 (cg-RX-API-DMAC7.html)
PL (2) PL2570128T3 (cg-RX-API-DMAC7.html)
PT (2) PT2570128T (cg-RX-API-DMAC7.html)
SG (1) SG186597A1 (cg-RX-API-DMAC7.html)
SI (2) SI1740177T1 (cg-RX-API-DMAC7.html)
TW (1) TWI363759B (cg-RX-API-DMAC7.html)
UA (1) UA95768C2 (cg-RX-API-DMAC7.html)
UY (1) UY28871A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005104745A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200608565B (cg-RX-API-DMAC7.html)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045914A1 (es) * 2003-07-17 2005-11-16 Glaxo Group Ltd Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
OA13270A (en) * 2003-10-17 2007-01-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists.
AR046225A1 (es) * 2003-11-04 2005-11-30 Glaxo Group Ltd Compuesto de 8-azoniabiciclo(3.2.1)octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos que lo comprende y uso del compuesto para preparar dicha composicion
US20090253908A1 (en) * 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
US20070185148A1 (en) * 2004-03-17 2007-08-09 Glaxo Group Limited M3 muscarinic acetylchoine receptor antagonists
US7384946B2 (en) * 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
JP2007531792A (ja) * 2004-04-05 2007-11-08 サマリタン，ファーマスーティカルス，インク． 抗ｈｉｖキヌクリジン化合物
MY144753A (en) * 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EP1747219A4 (en) * 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
EP1957075A4 (en) * 2004-11-15 2009-11-18 Glaxo Group Ltd NOVEL ANTAGONISTS OF ACETYLCHOLINE M3 TYPE MUSCARINIC RECEPTORS
WO2007016639A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2007022351A2 (en) * 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
PE20071227A1 (es) 2006-04-20 2008-02-18 Glaxo Group Ltd Compuestos derivados de indazol como moduladores del receptor de glucocorticoides
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
PT2046787E (pt) 2006-08-01 2011-06-15 Glaxo Group Ltd Compostos de pirazolo[3,4-b]piridina e sua utilização como inibidores de pde4
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
TW200946525A (en) 2008-02-06 2009-11-16 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
PE20091553A1 (es) 2008-02-06 2009-10-30 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
AR070562A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
ATE552255T1 (de) 2008-06-05 2012-04-15 Glaxo Group Ltd 4-aminoindazole
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
EP4578502A3 (en) 2009-02-26 2025-10-08 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
EP2408769A1 (en) 2009-03-17 2012-01-25 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
JO3025B1 (ar) 2009-04-30 2016-09-05 Glaxo Group Ltd الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
US20120238571A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Indazole derivatives as pi 3-kinase
JP2013512878A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド 新規化合物
US20120245171A1 (en) 2009-12-03 2012-09-27 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of pi3 kinases
WO2011094434A2 (en) * 2010-01-28 2011-08-04 Theron Pharmaceuticals, Inc. 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
KR20130111967A (ko) * 2010-06-22 2013-10-11 키에시 파르마슈티시 엣스. 피. 에이. 항무스카린성 약물을 포함하는 건조 분말 제제
EP2614058B1 (en) 2010-09-08 2015-07-08 GlaxoSmithKline Intellectual Property Development Limited POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
KR20140041699A (ko) 2011-06-08 2014-04-04 글락소 그룹 리미티드 우메클리디늄 및 코르티코스테로이드를 포함하는 조합물
CA2838031A1 (en) 2011-06-08 2012-12-13 Glaxo Group Limited Dry powder inhaler compositions comprising umeclidinium
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
RU2502743C1 (ru) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
US9273001B2 (en) * 2012-08-15 2016-03-01 Glaxo Group Limited Chemical process
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
JP6218940B2 (ja) * 2013-07-13 2017-10-25 ベイジン エフエスウェルカム テクノロジー ディベロップメント カンパニー リミテッド キニン系化合物、その光学異性体及びその製造方法と医薬用途
PE20160198A1 (es) * 2013-07-30 2016-04-21 Glaxosmithkline Ip Dev Ltd Composiciones topicas para el tratamiento de sudoracion excesiva y metodos para utilizar las mismas
US20160263109A1 (en) 2013-10-17 2016-09-15 Glaxosmithkline Intellectual Property Development Limited P13k inhibitor for treatment of respiratory disease
WO2015055690A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CA2948441A1 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
JP6758196B2 (ja) 2014-05-28 2020-09-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｃｏｐｄの治療におけるフルチカゾンフランカルボン酸エステル
CA2965590A1 (en) * 2014-11-03 2016-05-12 Olon S.P.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN105461710A (zh) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 一种芜地溴铵的制备方法
WO2017120559A1 (en) * 2016-01-08 2017-07-13 Theron Pharmaceuticals, Inc. Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
PT109740B (pt) 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (en) * 2017-03-08 2018-09-13 Gbr Laboratories Pvt. Ltd A process for the preparation of umeclidinium bromide and intermediates thereof
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
IT201700058796A1 (it) * 2017-05-30 2018-11-30 Olon Spa Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
AU2018357917B2 (en) 2017-10-30 2024-08-01 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN108558860B (zh) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
PT115583B (pt) 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
CA3173172A1 (en) 2020-03-26 2021-09-30 Christopher D. Kane Cathepsin inhibitors for preventing or treating viral infections
CN111484445B (zh) * 2020-04-21 2021-05-18 广东莱佛士制药技术有限公司 分离纯化高纯度乌美溴铵的中间体的方法
AU2021264829B2 (en) 2020-04-26 2024-02-01 Beijing Showby Pharmaceutical Co., Ltd. Crystal of M receptor antagonist as well as preparation method therefor and application thereof
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
CN112479983B (zh) * 2020-11-25 2022-07-12 江苏豪森药业集团有限公司 乌美溴铵中间体及其制备方法
PT117440B (pt) 2021-09-03 2024-04-26 Hovione Farm S A Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
JP2025517625A (ja) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ プレターゲティング
WO2024251812A1 (en) 2023-06-07 2024-12-12 Pharmazell Gmbh A process for the preparation of umeclidinium bromide intermediate

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1230087A (cg-RX-API-DMAC7.html) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
AT396333B (de) 1982-10-08 1993-08-25 Glaxo Group Ltd Vorrichtung zur verabreichung von medikamenten an patienten, einrichtung mit mehreren solchen vorrichtungen und traeger mit medikamentbehaeltern hiefuer
GR861995B (en) 1985-07-30 1986-11-04 Glaxo Group Ltd Devices for administering medicaments to patients
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5780466A (en) 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
WO1998024788A1 (en) 1996-12-02 1998-06-11 Georgetown University Tropane derivatives and method for their synthesis
US6248752B1 (en) 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
NZ526674A (en) * 2000-12-28 2005-03-24 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
NZ532283A (en) 2001-10-17 2005-06-24 Ucb S Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
EP1442037A1 (en) * 2001-11-09 2004-08-04 PHARMACIA & UPJOHN COMPANY Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
ES2425347T3 (es) * 2001-12-20 2013-10-14 Chiesi Farmaceutici S.P.A. Derivados de carbamato de 1-alquil-1-azoniabiciclo[2.2.2]octano y su uso como antagonistas de receptores muscarínicos
US6696462B2 (en) 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
AR040779A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
EP1613307A4 (en) 2003-04-07 2008-03-12 Glaxo Group Ltd M SB 3 / SB MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
TW200519109A (en) 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
AR045914A1 (es) 2003-07-17 2005-11-16 Glaxo Group Ltd Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
PE20050327A1 (es) 2003-07-17 2005-06-08 Glaxo Group Ltd Derivados de 8-azoniabiciclo[3.2.1]octano como antagonistas de los receptores muscarinicos de la acetilcolina
PT1677795E (pt) 2003-10-14 2011-04-01 Glaxo Group Ltd Antagonistas do receptor muscarínico de acetilcolina
OA13270A (en) 2003-10-17 2007-01-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists.
AR046225A1 (es) 2003-11-04 2005-11-30 Glaxo Group Ltd Compuesto de 8-azoniabiciclo(3.2.1)octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos que lo comprende y uso del compuesto para preparar dicha composicion
EP1685118B1 (en) 2003-11-21 2009-07-08 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
AR046784A1 (es) 2003-12-03 2005-12-21 Glaxo Group Ltd Compuesto de amina ciclica composicion farmaceutica que lo comprende y su uso para preparar esta ultima
UY28646A1 (es) 2003-12-03 2005-06-30 Glaxo Group Ltd Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
US20090253908A1 (en) 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
JP2007530451A (ja) 2004-03-11 2007-11-01 グラクソ　グループ　リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
US20070185148A1 (en) 2004-03-17 2007-08-09 Glaxo Group Limited M3 muscarinic acetylchoine receptor antagonists
EP1725240A4 (en) 2004-03-17 2009-03-25 Glaxo Group Ltd ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2005094835A1 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US7384946B2 (en) 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
JP2007538005A (ja) 2004-04-07 2007-12-27 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
MY144753A (en) * 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EP1747219A4 (en) 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
EP1749012A4 (en) 2004-05-28 2009-07-29 Glaxo Group Ltd ANTAGONISTS OF MUSCARIN ACETYLCHOLIN RECEPTOR
WO2006005057A2 (en) 2004-06-30 2006-01-12 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US20070293531A1 (en) 2004-08-05 2007-12-20 Jakob Busch-Petersen Muscarinic Acetycholine Receptor Antagonists
EP1781103A4 (en) 2004-08-06 2008-05-14 Glaxo Group Ltd ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2006050239A2 (en) 2004-10-29 2006-05-11 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
EP1827439A4 (en) 2004-11-15 2009-11-18 Glaxo Group Ltd NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
EP1957075A4 (en) 2004-11-15 2009-11-18 Glaxo Group Ltd NOVEL ANTAGONISTS OF ACETYLCHOLINE M3 TYPE MUSCARINIC RECEPTORS
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
WO2007016639A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2007016650A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2007022351A2 (en) 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Also Published As

Publication number Publication date
NZ549997A (en) 2010-10-29
JP5398871B2 (ja) 2014-01-29
WO2005104745A2 (en) 2005-11-10
EA021994B1 (ru) 2015-10-30
US8853404B2 (en) 2014-10-07
KR101037026B1 (ko) 2011-05-25
DK1740177T3 (da) 2012-10-29
ES2600405T3 (es) 2017-02-08
KR20110010841A (ko) 2011-02-07
PE20060259A1 (es) 2006-03-25
US20090124653A1 (en) 2009-05-14
EA201100019A1 (ru) 2011-12-30
US20140371264A1 (en) 2014-12-18
CY2014043I1 (el) 2015-12-09
CN102040602A (zh) 2011-05-04
US7498440B2 (en) 2009-03-03
HRP20161385T1 (hr) 2016-12-02
HRP20120832T1 (hr) 2012-11-30
FR14C0075I2 (fr) 2015-05-22
EA015033B1 (ru) 2011-04-29
NO2017017I1 (no) 2017-05-04
BE2014C063I2 (cg-RX-API-DMAC7.html) 2024-08-08
CY2014043I2 (el) 2015-12-09
PL1740177T3 (pl) 2012-12-31
HUS1400053I1 (hu) 2017-07-28
KR20070015412A (ko) 2007-02-02
MY144753A (en) 2011-10-31
JP2007534769A (ja) 2007-11-29
LU92565I2 (fr) 2014-12-02
US8309572B2 (en) 2012-11-13
US9144571B2 (en) 2015-09-29
EP2570128B1 (en) 2016-08-10
KR101152032B1 (ko) 2012-06-11
CY1118082T1 (el) 2017-06-28
CA2755954A1 (en) 2005-11-10
BRPI0510170B1 (pt) 2018-12-18
BRPI0510170A (pt) 2007-10-02
HK1102423A1 (en) 2007-11-23
NO2017018I1 (no) 2017-05-04
US20160002220A1 (en) 2016-01-07
CN1976701A (zh) 2007-06-06
ES2392848T4 (es) 2014-10-01
BRPI0510170B8 (pt) 2021-05-25
CY1113196T1 (el) 2015-12-09
CA2755954C (en) 2014-02-18
NO20065417L (no) 2006-12-29
US8183257B2 (en) 2012-05-22
NO338959B1 (no) 2016-11-07
EP2570128A1 (en) 2013-03-20
AU2005237576B2 (en) 2012-01-12
SI2570128T1 (sl) 2016-11-30
US20070185155A1 (en) 2007-08-09
US20070249664A1 (en) 2007-10-25
US20140080863A1 (en) 2014-03-20
ES2392848T3 (es) 2012-12-14
US20130030015A1 (en) 2013-01-31
ZA200608565B (en) 2019-12-18
PT2570128T (pt) 2016-10-07
NL300694I1 (cg-RX-API-DMAC7.html) 2015-12-29
MXPA06012405A (es) 2007-01-17
TW200605887A (en) 2006-02-16
SG186597A1 (en) 2013-01-30
AR050902A1 (es) 2006-12-06
US20150238470A1 (en) 2015-08-27
EP1740177A2 (en) 2007-01-10
HUE031304T2 (hu) 2017-07-28
PT1740177E (pt) 2012-11-02
UA95768C2 (ru) 2011-09-12
UY28871A1 (es) 2005-11-30
TWI363759B (en) 2012-05-11
LU92565I9 (cg-RX-API-DMAC7.html) 2019-01-17
SI1740177T1 (sl) 2012-12-31
JP5014121B2 (ja) 2012-08-29
WO2005104745A3 (en) 2006-08-03
IL178152A0 (en) 2006-12-31
DK2570128T3 (en) 2016-11-07
EP1740177A4 (en) 2010-05-05
EA200601991A1 (ru) 2007-02-27
CA2564742A1 (en) 2005-11-10
ECSP066940A (es) 2006-12-20
IL178152A (en) 2011-05-31
MA28631B1 (fr) 2007-06-01
US8575347B2 (en) 2013-11-05
NO2017018I2 (no) 2018-05-14
PL2570128T3 (pl) 2017-09-29
AU2005237576A1 (en) 2005-11-10
US20120157491A1 (en) 2012-06-21
US7488827B2 (en) 2009-02-10
EP1740177B1 (en) 2012-08-08
JP2012162559A (ja) 2012-08-30
FR14C0075I1 (fr) 2014-11-21
US9045469B2 (en) 2015-06-02
AP2213A (en) 2011-03-01
EP3111936A1 (en) 2017-01-04
LT2570128T (lt) 2016-10-10
NL300694I2 (cg-RX-API-DMAC7.html) 2015-12-29
AP2006003746A0 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
CA2564742C (en) Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists
US7767691B2 (en) Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
US7598267B2 (en) Muscarinic acetylcholine receptor antagonists
AU2012202307B2 (en) Muscarinic acetylcholine receptor antagonists
HK1102423B (en) Muscarinic acetylcholine receptor antagonists

Legal Events

Date Code Title Description
EEER Examination request